• Results
  • Access strategies: Results Part II: Do companies extend access terms for countrie...
Access strategies: Results Part II

Do companies extend access terms for countries outside supranational agreements?

This part two of a four part series, describes how supranational agreements help solved access challenges and takes a look at whether companies extend the same terms of access for their products to countries which are not covered by these agreements. 

Explore further

How we measure

How we measure

The Index evaluates pharmaceutical companies in areas where they have the biggest potential and responsibility to make change, such as R&D and pricing. Find out more about the analytical framework and areas of evaluation.

Get in touch

Back to top |